PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22726381-1 2012 BACKGROUND: The 5-lipoxygenase activating protein (FLAP), encoded by the activating 5-lipoxygenase (ALOX5AP) gene, is a crucial mediator of the biosynthesis of leukotrienes, which have been implicated in atherosclerosis. Leukotrienes 160-172 arachidonate 5-lipoxygenase activating protein Homo sapiens 51-55 23015755-2 2012 To initiate LT formation, the 5-lipoxygenase (5-LO) enzyme translocates to nuclear membranes, where it associates with its scaffold protein, 5-lipoxygenase-activating protein (FLAP), to form the core of the multiprotein LT synthetic complex. Leukotrienes 12-14 arachidonate 5-lipoxygenase activating protein Homo sapiens 176-180 22726381-1 2012 BACKGROUND: The 5-lipoxygenase activating protein (FLAP), encoded by the activating 5-lipoxygenase (ALOX5AP) gene, is a crucial mediator of the biosynthesis of leukotrienes, which have been implicated in atherosclerosis. Leukotrienes 160-172 arachidonate 5-lipoxygenase activating protein Homo sapiens 100-107 22206291-1 2011 BACKGROUND: We have previously shown evidence that polymorphisms within genes controlling leukotriene B4 (LTB4) production (ALOX5AP and LTA4H) are associated with asthma susceptibility in children. Leukotrienes 90-101 arachidonate 5-lipoxygenase activating protein Homo sapiens 124-131 22607880-0 2012 Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). Leukotrienes 67-78 arachidonate 5-lipoxygenase activating protein Homo sapiens 158-162 22607880-1 2012 Pharmacological suppression of leukotriene biosynthesis by 5-lipoxygenase (5-LO)-activating protein (FLAP) inhibitors is a promising strategy to intervene with inflammatory, allergic and cardiovascular diseases. Leukotrienes 31-42 arachidonate 5-lipoxygenase activating protein Homo sapiens 101-105 22607880-3 2012 Compound 7 potently suppressed leukotriene formation in intact neutrophils (IC(50)=0.31 muM) but essentially failed to directly inhibit 5-LO suggesting that interaction with FLAP causes inhibition of leukotriene synthesis. Leukotrienes 200-211 arachidonate 5-lipoxygenase activating protein Homo sapiens 174-178 22222457-2 2012 The integral nuclear membrane protein 5-lipoxygenase-activating protein (FLAP) is essential for leukotriene biosynthesis in response to cellular activation. Leukotrienes 96-107 arachidonate 5-lipoxygenase activating protein Homo sapiens 73-77 22222457-4 2012 Inhibitors are bound within the lipid-exposed portion of FLAP, and the unexpected location of the inhibitor-binding site suggests a transport mechanism for arachidonic acid and provides functional insights into leukotriene biosynthesis. Leukotrienes 211-222 arachidonate 5-lipoxygenase activating protein Homo sapiens 57-61 20810156-7 2010 CONCLUSION: LTA4H and ALOX5AP gene polymorphisms modify the augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Ricans but not Mexicans with asthma. Leukotrienes 109-120 arachidonate 5-lipoxygenase activating protein Homo sapiens 22-29 21248314-2 2011 The initial catalytic step in the formation of leukotrienes is catalyzed by 5-lipoxygenase (5-LOX) in conjunction with its activating partner protein FLAP. Leukotrienes 47-59 arachidonate 5-lipoxygenase activating protein Homo sapiens 150-154 20810156-0 2010 ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. Leukotrienes 88-99 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-7 19876784-2 2009 Leukotriene synthesis requires 5-lipoxygenase activating protein (FLAP), which acts as a scaffolding protein for the assembly of other enzymes involved in the leukotriene synthetic pathway occurring at the nuclear envelope of leukocytes. Leukotrienes 0-11 arachidonate 5-lipoxygenase activating protein Homo sapiens 66-70 20067482-1 2010 BACKGROUND: Leukotrienes play an important role in allergic and inflammatory diseases, but reports on the involvement of arachidonate 5-lipoxygenase-activating protein (ALOX5AP) and leukotriene A(4) hydrolase (LTA4H) in asthma have been inconclusive. Leukotrienes 12-24 arachidonate 5-lipoxygenase activating protein Homo sapiens 121-167 20067482-1 2010 BACKGROUND: Leukotrienes play an important role in allergic and inflammatory diseases, but reports on the involvement of arachidonate 5-lipoxygenase-activating protein (ALOX5AP) and leukotriene A(4) hydrolase (LTA4H) in asthma have been inconclusive. Leukotrienes 12-24 arachidonate 5-lipoxygenase activating protein Homo sapiens 169-176 20194722-3 2010 Our studies showed hypoxia augmented the expression of 5-lipoxygenase activating protein (FLAP), a key enzyme in leukotriene formation, in both human pulmonary microvascular endothelial cells and a transformed human brain endothelial cell line. Leukotrienes 113-124 arachidonate 5-lipoxygenase activating protein Homo sapiens 90-94 19876784-2 2009 Leukotriene synthesis requires 5-lipoxygenase activating protein (FLAP), which acts as a scaffolding protein for the assembly of other enzymes involved in the leukotriene synthetic pathway occurring at the nuclear envelope of leukocytes. Leukotrienes 159-170 arachidonate 5-lipoxygenase activating protein Homo sapiens 66-70 19876784-3 2009 By blocking the formation of both leukotriene B4 and the cysteinyl leukotrienes (ie, LTC4 , LTD4 and LTE4), FLAP inhibitors act as broad-spectrum leukotriene-modifier drugs that may have a wide range of therapeutic applications. Leukotrienes 34-45 arachidonate 5-lipoxygenase activating protein Homo sapiens 108-112 18398223-5 2008 RELEVANCE FOR NURSING PRACTICE: Through the inhibition of the ALOX5AP gene by downregulation of the leukotriene pathway, the risk of ACS may be decreased in individuals that carry susceptibility allele(s). Leukotrienes 100-111 arachidonate 5-lipoxygenase activating protein Homo sapiens 62-69 19456278-1 2009 BACKGROUND: 5-Lipoxygenase activating protein (FLAP) has been implicated in a number of different pathophysiological conditions owing to its involvement in leukotriene synthesis. Leukotrienes 156-167 arachidonate 5-lipoxygenase activating protein Homo sapiens 47-51 18775537-2 2009 BACKGROUND: The ALOX5AP gene is required for the synthesis of leukotrienes, a protein family involved in inflammatory responses. Leukotrienes 62-74 arachidonate 5-lipoxygenase activating protein Homo sapiens 16-23 19130089-2 2009 Recently, leukotriene-based inflammation has also been shown to play an important role in atherosclerosis: ALOX5AP and LTA4H, both genes in the leukotriene biosynthesis pathway, have individually been shown to be associated with various cardiovascular disease (CVD) phenotypes. Leukotrienes 10-21 arachidonate 5-lipoxygenase activating protein Homo sapiens 107-114 19130089-2 2009 Recently, leukotriene-based inflammation has also been shown to play an important role in atherosclerosis: ALOX5AP and LTA4H, both genes in the leukotriene biosynthesis pathway, have individually been shown to be associated with various cardiovascular disease (CVD) phenotypes. Leukotrienes 144-155 arachidonate 5-lipoxygenase activating protein Homo sapiens 107-114 19239910-1 2009 MK-886, an inhibitor of the 5-lipoxygenase-activating protein (FLAP), potently suppresses leukotriene biosynthesis in intact cells and is frequently used to define a role of the 5-lipoxygenase (EC 1.13.11.34) pathway in cellular or animal models of inflammation, allergy, cancer, and cardiovascular disease. Leukotrienes 90-101 arachidonate 5-lipoxygenase activating protein Homo sapiens 63-67 18374923-11 2008 CONCLUSIONS: ALOX5AP, a gene within the inflammatory leukotriene pathway linked to and associated with coronary atherosclerosis, is also associated with in-stent restenosis. Leukotrienes 53-64 arachidonate 5-lipoxygenase activating protein Homo sapiens 13-20 18187210-4 2008 The first committed step in the synthesis of leukotrienes is the oxidation of arachidonic acid (AA) by 5-lipoxygenase (5-LO), and the integral membrane protein 5-lipoxygenase-activating protein (FLAP) is an essential partner of 5-LO for this process. Leukotrienes 45-57 arachidonate 5-lipoxygenase activating protein Homo sapiens 195-199 18187210-5 2008 FLAP was molecularly identified via a photoaffinity probe and an affinity gel based on MK-886, a selective leukotriene inhibitor that has no activity against broken-cell preparations of 5-LO. Leukotrienes 107-118 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 17504658-4 2007 Exercise increases the distribution of leukotrienes and influences the leukotriene transcription pathway; it could be shown that the genes ALOX5 and ALOX5AP encoding for 5-lipooxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) as well as activators for 5-LO, p38 -mitogen-activated protein kinase (MAPK), and others, are enhanced after exercise in healthy subjects. Leukotrienes 39-51 arachidonate 5-lipoxygenase activating protein Homo sapiens 149-156 17600184-2 2007 The integral membrane protein FLAP is essential for leukotriene biosynthesis. Leukotrienes 52-63 arachidonate 5-lipoxygenase activating protein Homo sapiens 30-34 17600184-3 2007 We describe the x-ray crystal structures of human FLAP in complex with two leukotriene biosynthesis inhibitors at 4.0 and 4.2 angstrom resolution, respectively. Leukotrienes 75-86 arachidonate 5-lipoxygenase activating protein Homo sapiens 50-54 17600184-4 2007 The structures show that inhibitors bind in membrane-embedded pockets of FLAP, which suggests how these inhibitors prevent arachidonic acid from binding to FLAP and subsequently being transferred to 5-lipoxygenase, thereby preventing leukotriene biosynthesis. Leukotrienes 234-245 arachidonate 5-lipoxygenase activating protein Homo sapiens 73-77 17600184-4 2007 The structures show that inhibitors bind in membrane-embedded pockets of FLAP, which suggests how these inhibitors prevent arachidonic acid from binding to FLAP and subsequently being transferred to 5-lipoxygenase, thereby preventing leukotriene biosynthesis. Leukotrienes 234-245 arachidonate 5-lipoxygenase activating protein Homo sapiens 156-160 17504658-4 2007 Exercise increases the distribution of leukotrienes and influences the leukotriene transcription pathway; it could be shown that the genes ALOX5 and ALOX5AP encoding for 5-lipooxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) as well as activators for 5-LO, p38 -mitogen-activated protein kinase (MAPK), and others, are enhanced after exercise in healthy subjects. Leukotrienes 39-50 arachidonate 5-lipoxygenase activating protein Homo sapiens 149-156 16716917-8 2006 Therefore, the leukotriene biosynthesis inhibitory effect of knipholone was evident by its ability either to inhibit the 5-lipoxygenase activating protein (FLAP) or as a competitive (non-redox) inhibitor of the enzyme. Leukotrienes 15-26 arachidonate 5-lipoxygenase activating protein Homo sapiens 156-160 16987874-3 2006 Although there was limited inter-study concordance of important loci, two gene variants in the leukotriene pathway (ALOX5AP and LTA4) have emerged as susceptibility factors for myocardial infarction (MI). Leukotrienes 95-106 arachidonate 5-lipoxygenase activating protein Homo sapiens 116-123 15625306-1 2005 We examined induced expression of the 5-lipoxygenase-activating protein (FLAP), which is critical for leukotriene synthesis in mononuclear phagocytes. Leukotrienes 102-113 arachidonate 5-lipoxygenase activating protein Homo sapiens 73-77 16144515-1 2006 FLAP (5-lipoxygenase-activating protein) is a nuclear transmembrane protein involved in the biosynthesis of LTs (leukotrienes) and other 5-LO (5-lipoxygenase) products. Leukotrienes 108-111 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 16144515-1 2006 FLAP (5-lipoxygenase-activating protein) is a nuclear transmembrane protein involved in the biosynthesis of LTs (leukotrienes) and other 5-LO (5-lipoxygenase) products. Leukotrienes 113-125 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 17156456-3 2006 We studied whether the expression of 5-lipoxygenase (5-LO) or 5-LO-activating protein (FLAP) is responsible for the shunt from prostaglandins to leukotrienes. Leukotrienes 145-157 arachidonate 5-lipoxygenase activating protein Homo sapiens 87-91 15581413-3 2004 5-LOX is an enzyme that, in association with 5-LOX-activating protein (FLAP), leads to the synthesis of leukotrienes from omega-6 arachidonic acid. Leukotrienes 104-116 arachidonate 5-lipoxygenase activating protein Homo sapiens 71-75 14770184-6 2004 We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by increasing leukotriene production and inflammation in the arterial wall. Leukotrienes 125-136 arachidonate 5-lipoxygenase activating protein Homo sapiens 29-36 10036194-1 1999 Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is an arachidonic acid binding protein that has been shown to be critical in the biosynthesis of leukotrienes. Leukotrienes 154-166 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-46 11035107-2 2000 We used in situ PCR in this model of human asthma to detect lung mRNA for 5-lipoxygenase (5-LO) and 5-LO-activating protein (FLAP), key proteins necessary for leukotriene synthesis. Leukotrienes 159-170 arachidonate 5-lipoxygenase activating protein Homo sapiens 125-129 12571239-2 2003 We examined expression of the 5-lipoxygenase activating protein (FLAP), which is critical for inflammatory cell leukotriene synthesis. Leukotrienes 112-123 arachidonate 5-lipoxygenase activating protein Homo sapiens 65-69 10381823-2 1999 5-lipoxygenase (5-LOX) catalyses the first steps in the synthesis of leukotrienes from arachidonic acid, and its activity is dependent on 5-LOX activating protein (FLAP). Leukotrienes 69-81 arachidonate 5-lipoxygenase activating protein Homo sapiens 164-168 10036194-1 1999 Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is an arachidonic acid binding protein that has been shown to be critical in the biosynthesis of leukotrienes. Leukotrienes 154-166 arachidonate 5-lipoxygenase activating protein Homo sapiens 48-55 9375956-22 1997 However, the glucocorticoid-mediated induction of FLAP may provide a mechanism to maintain leukotriene biosynthesis through more efficient transfer of arachidonic acid to the 5-lipoxygenase reaction, in spite of inhibitory effects on other enzymes of the biosynthetic pathway. Leukotrienes 91-102 arachidonate 5-lipoxygenase activating protein Homo sapiens 50-54 9804170-1 1998 Five-lipoxygenase-activating protein (FLAP) is usually described as an essential protein to activate the leukotriene (LTs) synthesis via the 5-lipoxygenase pathway. Leukotrienes 105-116 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-36 9804170-1 1998 Five-lipoxygenase-activating protein (FLAP) is usually described as an essential protein to activate the leukotriene (LTs) synthesis via the 5-lipoxygenase pathway. Leukotrienes 105-116 arachidonate 5-lipoxygenase activating protein Homo sapiens 38-42 9804170-3 1998 Therefore HT29 cl.19A represents an original mammalian model to study FLAP-dependent leukotriene synthesis. Leukotrienes 85-96 arachidonate 5-lipoxygenase activating protein Homo sapiens 70-74 9630716-4 1998 MK-886, a potent inhibitor of leukotriene biosynthesis, blocked the FLAP dependent S.t.LOX activation after preincubation with FLAP transfected membranes. Leukotrienes 30-41 arachidonate 5-lipoxygenase activating protein Homo sapiens 68-72 9630716-4 1998 MK-886, a potent inhibitor of leukotriene biosynthesis, blocked the FLAP dependent S.t.LOX activation after preincubation with FLAP transfected membranes. Leukotrienes 30-41 arachidonate 5-lipoxygenase activating protein Homo sapiens 127-131 9445303-2 1998 Leukotriene production by perivascular and alveolar macrophages relies on activation of 5-lipoxygenase (5-LO), with translocation of the enzyme to the nuclear membrane, and association with the 5-LO activating protein (FLAP). Leukotrienes 0-11 arachidonate 5-lipoxygenase activating protein Homo sapiens 219-223 8245774-3 1993 FLAP is an 18-kD membrane bound protein that is essential for leukotriene synthesis in cells. Leukotrienes 62-73 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 9150468-1 1997 Human peripheral blood monocytes (HPBMs) express 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP), and hence have an ability to synthesize proinflammatory leukotrienes (LTs). Leukotrienes 163-175 arachidonate 5-lipoxygenase activating protein Homo sapiens 100-104 7738170-1 1995 5-Lipoxygenase (5-LO) and 5-lipoxygenase-activating protein (FLAP) are two key proteins involved in the synthesis of leukotrienes (LT) from arachidonic acid. Leukotrienes 117-129 arachidonate 5-lipoxygenase activating protein Homo sapiens 61-65 7738170-10 1995 These results indicate that the nuclear envelope is the site at which 5-LO interacts with FLAP and arachidonic acid to catalyze LT synthesis in activated AM as well as PBL, and that in resting AM the euchromatin region of the nucleus is the predominant source of the translocated enzyme. Leukotrienes 128-130 arachidonate 5-lipoxygenase activating protein Homo sapiens 90-94 7556168-6 1995 Furthermore, MK886, the FLAP-binding cellular leukotriene biosynthesis inhibitor, reduced both LTB4 and 5-HETE formation. Leukotrienes 46-57 arachidonate 5-lipoxygenase activating protein Homo sapiens 24-28 7741044-0 1994 Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Leukotrienes 22-33 arachidonate 5-lipoxygenase activating protein Homo sapiens 45-49 7741044-2 1994 Presently, two types of inhibitors are known, direct 5-LOX inhibitors (LOI) and the FLAP (five lipoxygenase activating protein) binding leukotriene synthesis inhibitors (LSI). Leukotrienes 136-147 arachidonate 5-lipoxygenase activating protein Homo sapiens 84-88 7741044-2 1994 Presently, two types of inhibitors are known, direct 5-LOX inhibitors (LOI) and the FLAP (five lipoxygenase activating protein) binding leukotriene synthesis inhibitors (LSI). Leukotrienes 136-147 arachidonate 5-lipoxygenase activating protein Homo sapiens 90-126 7741044-7 1994 The use of BAY X 1005 has helped to elucidate part of the complex FLAP/5-LOX interaction by showing that FLAP appears to represent a 5-LOX substrate transfer protein channelling endogenous and exogenous arachidonic acid to the leukotriene synthetizing 5-LOX. Leukotrienes 227-238 arachidonate 5-lipoxygenase activating protein Homo sapiens 66-70 7741044-7 1994 The use of BAY X 1005 has helped to elucidate part of the complex FLAP/5-LOX interaction by showing that FLAP appears to represent a 5-LOX substrate transfer protein channelling endogenous and exogenous arachidonic acid to the leukotriene synthetizing 5-LOX. Leukotrienes 227-238 arachidonate 5-lipoxygenase activating protein Homo sapiens 105-109 8049076-4 1994 Importantly, AM contained 40-fold more 5-lipoxygenase activating protein (FLAP) than did PBM, which correlated well with the relative abilities of intact AM and PBM to metabolize endogenous AA to leukotrienes. Leukotrienes 196-208 arachidonate 5-lipoxygenase activating protein Homo sapiens 74-78 8049076-6 1994 These observations indicate that, although FLAP is essential for the synthesis of leukotrienes from endogenous AA, perhaps by presenting AA to 5-LO, it is not required for 5-LO metabolism of exogenous AA. Leukotrienes 82-94 arachidonate 5-lipoxygenase activating protein Homo sapiens 43-47 8049076-7 1994 The differing roles of FLAP in 5-LO metabolism of endogenous versus exogenous AA are consistent with the conclusion that it is the markedly greater expression of FLAP, rather than of 5-LO, that is primarily responsible for the increased leukotriene synthesis from endogenous AA that accompanies PBM differentiation into AM. Leukotrienes 237-248 arachidonate 5-lipoxygenase activating protein Homo sapiens 162-166 8145039-12 1994 The increase in FLAP expression induced by GM-CSF in inflammatory conditions could confer upon neutrophils a prolonged capacity to synthesize leukotrienes. Leukotrienes 142-154 arachidonate 5-lipoxygenase activating protein Homo sapiens 16-20 8114608-3 1994 Binding of leukotriene biosynthesis inhibitors to FLAP mutants containing deletions of 2 to 6 amino acids within the region from residue 48-61 was undetectable. Leukotrienes 11-22 arachidonate 5-lipoxygenase activating protein Homo sapiens 50-54 8440384-1 1993 5-Lipoxygenase-activating protein (FLAP) is an 18-kDa integral membrane protein which is essential for cellular leukotriene (LT) synthesis, and is the target of LT biosynthesis inhibitors. Leukotrienes 112-123 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 8344271-1 1993 5-Lipoxygenase (5-LO) and its activating protein (FLAP) are both required for cellular leukotriene (LT) synthesis, with 5-LO catalyzing both the synthesis of (5S)-5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE) from arachidonic acid and the subsequent synthesis of LTA4 from 5-HPETE. Leukotrienes 87-98 arachidonate 5-lipoxygenase activating protein Homo sapiens 50-54 8344271-1 1993 5-Lipoxygenase (5-LO) and its activating protein (FLAP) are both required for cellular leukotriene (LT) synthesis, with 5-LO catalyzing both the synthesis of (5S)-5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE) from arachidonic acid and the subsequent synthesis of LTA4 from 5-HPETE. Leukotrienes 100-102 arachidonate 5-lipoxygenase activating protein Homo sapiens 50-54 1469057-6 1992 Thus, it was determined that FLAP was required for the cellular synthesis of leukotrienes. Leukotrienes 77-89 arachidonate 5-lipoxygenase activating protein Homo sapiens 29-33 8357989-1 1993 5-Lipoxygenase-activating protein (FLAP) plays an essential role in cellular leukotriene (LT) synthesis and represents the target of three classes of LT biosynthesis inhibitors. Leukotrienes 77-88 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 1469057-1 1992 In a previous study, osteosarcoma cells expressing both 5-lipoxygenase (5-LO) and 5 lipoxygenase-activating protein (FLAP) synthesized leukotrienes upon A23187 stimulation (Dixon, R. A. F., R. E. Diehl, E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard, and D. K. Miller. Leukotrienes 135-147 arachidonate 5-lipoxygenase activating protein Homo sapiens 117-121 1588922-0 1992 Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Leukotrienes 138-149 arachidonate 5-lipoxygenase activating protein Homo sapiens 95-132 1480129-1 1992 To identify regions of 5-lipoxygenase-activating protein (FLAP) important for the function of the protein and the binding of leukotriene biosynthesis inhibitors, we performed a cross-species analysis of FLAP. Leukotrienes 125-136 arachidonate 5-lipoxygenase activating protein Homo sapiens 58-62 1480129-2 1992 FLAP from all 10 mammalian species analyzed (human, monkey, horse, pig, cow, sheep, rabbit, dog, rat, and mouse) were immunologically cross-reactive and specifically bound leukotriene biosynthesis inhibitors with high affinity. Leukotrienes 172-183 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 1635556-1 1992 5-Lipoxygenase-activating protein (FLAP) is specifically labeled by [125I]L-669,083 and [125I]L-691,678, photoaffinity analogues of two classes of potent leukotriene biosynthesis inhibitors. Leukotrienes 154-165 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 1635556-11 1992 The roles that amino acid residues in the carboxyl-terminal half of the first hydrophilic loop of FLAP may play in the binding of leukotriene biosynthesis inhibitors are currently under investigation. Leukotrienes 130-141 arachidonate 5-lipoxygenase activating protein Homo sapiens 98-102 1588922-1 1992 A binding assay has been developed to measure the affinity of leukotriene synthesis inhibitors for 5-lipoxygenase-activating protein (FLAP), using human leukocyte membranes as the source of FLAP and a radioiodinated leukotriene synthesis inhibitor, 125I-L-691,831, as ligand. Leukotrienes 62-73 arachidonate 5-lipoxygenase activating protein Homo sapiens 95-132 1588922-1 1992 A binding assay has been developed to measure the affinity of leukotriene synthesis inhibitors for 5-lipoxygenase-activating protein (FLAP), using human leukocyte membranes as the source of FLAP and a radioiodinated leukotriene synthesis inhibitor, 125I-L-691,831, as ligand. Leukotrienes 62-73 arachidonate 5-lipoxygenase activating protein Homo sapiens 134-138 1588922-1 1992 A binding assay has been developed to measure the affinity of leukotriene synthesis inhibitors for 5-lipoxygenase-activating protein (FLAP), using human leukocyte membranes as the source of FLAP and a radioiodinated leukotriene synthesis inhibitor, 125I-L-691,831, as ligand. Leukotrienes 216-227 arachidonate 5-lipoxygenase activating protein Homo sapiens 95-132 1588922-1 1992 A binding assay has been developed to measure the affinity of leukotriene synthesis inhibitors for 5-lipoxygenase-activating protein (FLAP), using human leukocyte membranes as the source of FLAP and a radioiodinated leukotriene synthesis inhibitor, 125I-L-691,831, as ligand. Leukotrienes 216-227 arachidonate 5-lipoxygenase activating protein Homo sapiens 134-138 1588922-4 1992 An excellent correlation was shown between affinity for FLAP in the binding assay and inhibition of leukotriene synthesis in human polymorphonuclear leukocytes for compounds from two structurally distinct classes, namely indoles and quinolines. Leukotrienes 100-111 arachidonate 5-lipoxygenase activating protein Homo sapiens 56-60 1588922-7 1992 This study validates a selective binding assay for leukotriene synthesis inhibitors whose protein target is FLAP. Leukotrienes 51-62 arachidonate 5-lipoxygenase activating protein Homo sapiens 108-112 1857337-2 1991 It was demonstrated that the 18-kDa protein is necessary for the cellular activation of leukotriene synthesis and was named 5-lipoxygenase-activating protein (FLAP). Leukotrienes 88-99 arachidonate 5-lipoxygenase activating protein Homo sapiens 159-163 1857337-5 1991 To determine whether FLAP is the protein target of leukotriene synthesis inhibitors of the quinoline class, we investigated the ability of these compounds to inhibit photoaffinity labeling of FLAP and to elute FLAP from indole affinity gels. Leukotrienes 51-62 arachidonate 5-lipoxygenase activating protein Homo sapiens 21-25 1857337-6 1991 The abilities of the quinoline inhibitors to interact with FLAP correlated well with their abilities to inhibit leukotriene synthesis in human polymorphonuclear leukocytes. Leukotrienes 112-123 arachidonate 5-lipoxygenase activating protein Homo sapiens 59-63 1857337-10 1991 These results suggest a direct binding site for the quinoline leukotriene synthesis inhibitors on FLAP and provide further evidence for the essential role of FLAP in cellular leukotriene synthesis. Leukotrienes 62-73 arachidonate 5-lipoxygenase activating protein Homo sapiens 98-102 1857337-10 1991 These results suggest a direct binding site for the quinoline leukotriene synthesis inhibitors on FLAP and provide further evidence for the essential role of FLAP in cellular leukotriene synthesis. Leukotrienes 62-73 arachidonate 5-lipoxygenase activating protein Homo sapiens 158-162 34971430-0 2021 Ethoxy acetalated dextran-based nanocarriers accomplish efficient inhibition of leukotriene formation by a novel FLAP antagonist in human leukocytes and blood. Leukotrienes 80-91 arachidonate 5-lipoxygenase activating protein Homo sapiens 113-117 2024291-0 1991 FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Leukotrienes 58-70 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 2024291-1 1991 FLAP (5-lipoxygenase-activating protein) is a novel 18 kDa membrane protein that together with 5-lipoxygenase is required for cellular leukotriene biosynthesis. Leukotrienes 135-146 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-4 2024291-2 1991 Tony Ford-Hutchinson describes a novel class of leukotriene biosynthesis inhibitor, exemplified by MK0886, that can bind to FLAP with high affinity, prevent the activation of 5-lipoxygenase by preventing the translocation of the enzyme from the cytosol to the membrane and inhibit leukotriene production. Leukotrienes 48-59 arachidonate 5-lipoxygenase activating protein Homo sapiens 124-128 2024291-2 1991 Tony Ford-Hutchinson describes a novel class of leukotriene biosynthesis inhibitor, exemplified by MK0886, that can bind to FLAP with high affinity, prevent the activation of 5-lipoxygenase by preventing the translocation of the enzyme from the cytosol to the membrane and inhibit leukotriene production. Leukotrienes 281-292 arachidonate 5-lipoxygenase activating protein Homo sapiens 124-128 2174053-1 1990 Previous studies involving transfection of cDNAs for 5-lipoxygenase-activating protein (FLAP) and 5-lipoxygenase into osteosarcoma cells have shown that both these proteins are essential for leukotriene synthesis (Dixon, R. A. F., Diehl, R. E., Opas, E., Rands, E., Vickers, P. J., Evans, J. F., Gillard, J. W., and Miller, D. K. (1990) Nature 343, 282-284). Leukotrienes 191-202 arachidonate 5-lipoxygenase activating protein Homo sapiens 88-92 2174053-2 1990 In the present study we show that FLAP is present in a variety of cells known to produce leukotrienes, but is absent from a number of cells which do not synthesize leukotrienes. Leukotrienes 89-101 arachidonate 5-lipoxygenase activating protein Homo sapiens 34-38 2174053-2 1990 In the present study we show that FLAP is present in a variety of cells known to produce leukotrienes, but is absent from a number of cells which do not synthesize leukotrienes. Leukotrienes 164-176 arachidonate 5-lipoxygenase activating protein Homo sapiens 34-38 2174053-4 1990 Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP. Leukotrienes 9-20 arachidonate 5-lipoxygenase activating protein Homo sapiens 75-79 2174053-4 1990 Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP. Leukotrienes 9-20 arachidonate 5-lipoxygenase activating protein Homo sapiens 196-200 2174053-4 1990 Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP. Leukotrienes 114-125 arachidonate 5-lipoxygenase activating protein Homo sapiens 75-79 2174053-4 1990 Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP. Leukotrienes 114-125 arachidonate 5-lipoxygenase activating protein Homo sapiens 196-200 2300173-5 1990 We also demonstrate that the expression of both the MK-886-binding protein and 5-lipoxygenase is necessary for leukotriene synthesis in intact cells. Leukotrienes 111-122 arachidonate 5-lipoxygenase activating protein Homo sapiens 52-74 34971430-1 2021 Leukotrienes are pro-inflammatory lipid mediators generated by 5-lipoxygenase aided by the 5-lipoxygenase-activating protein (FLAP). Leukotrienes 0-12 arachidonate 5-lipoxygenase activating protein Homo sapiens 126-130 34971430-2 2021 BRP-201, a novel benzimidazole-based FLAP antagonist, inhibits leukotriene biosynthesis in isolated leukocytes. Leukotrienes 63-74 arachidonate 5-lipoxygenase activating protein Homo sapiens 37-41 34971430-10 2021 These results reveal the feasibility of our pharmacological approach using a novel FLAP antagonist encapsulated into Ace-DEX-based NPs with improved efficiency in blood to suppress leukotriene biosynthesis. Leukotrienes 181-192 arachidonate 5-lipoxygenase activating protein Homo sapiens 83-87 34805632-3 2021 AZD5718 is a potent, selective, and reversible 5-lipoxygenase activating protein (FLAP) inhibitor that suppresses leukotriene production. Leukotrienes 114-125 arachidonate 5-lipoxygenase activating protein Homo sapiens 82-86 34765025-1 2021 5-lipoxygenase-activating protein (FLAP), encoded by the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene, can adjust the biogenesis of proinflammatory leukotrienes to increase the adhesion and permeability of the vascular internal wall. Leukotrienes 165-177 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 34765025-1 2021 5-lipoxygenase-activating protein (FLAP), encoded by the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene, can adjust the biogenesis of proinflammatory leukotrienes to increase the adhesion and permeability of the vascular internal wall. Leukotrienes 165-177 arachidonate 5-lipoxygenase activating protein Homo sapiens 57-103 34765025-1 2021 5-lipoxygenase-activating protein (FLAP), encoded by the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene, can adjust the biogenesis of proinflammatory leukotrienes to increase the adhesion and permeability of the vascular internal wall. Leukotrienes 165-177 arachidonate 5-lipoxygenase activating protein Homo sapiens 105-112 35300294-2 2022 The biological synthesis of leukotrienes is instigated by transfer of AA to 5-lipoxygenase (5-LO) via the 5-lipoxygenase-activating protein (FLAP). Leukotrienes 28-40 arachidonate 5-lipoxygenase activating protein Homo sapiens 141-145 34094977-3 2021 ALOX5AP (Arachidonate 5-Lipoxygenase Activating Protein) is a key enzyme in converting arachidonic acid to leukotriene: a crucial immune-modulating lipid mediator. Leukotrienes 107-118 arachidonate 5-lipoxygenase activating protein Homo sapiens 0-7 34094977-3 2021 ALOX5AP (Arachidonate 5-Lipoxygenase Activating Protein) is a key enzyme in converting arachidonic acid to leukotriene: a crucial immune-modulating lipid mediator. Leukotrienes 107-118 arachidonate 5-lipoxygenase activating protein Homo sapiens 9-55 35173459-0 2022 Shifting the Biosynthesis of Leukotrienes Toward Specialized Pro-Resolving Mediators by the 5-Lipoxygenase-Activating Protein (FLAP) Antagonist BRP-201. Leukotrienes 29-41 arachidonate 5-lipoxygenase activating protein Homo sapiens 127-131 35173459-2 2022 Proinflammatory leukotrienes (LTs), generated by 5-lipoxygenase (LOX) and the 5-LOX-activating protein (FLAP), initiate and maintain inflammation while specialized pro-resolving mediators (SPMs) formed by various LOXs as key enzymes promote inflammation resolution and the return to homeostasis. Leukotrienes 30-33 arachidonate 5-lipoxygenase activating protein Homo sapiens 104-108 35173459-4 2022 Here, we demonstrated that the FLAP antagonist BRP-201 possesses such pharmacological profile and causes a switch from LT toward SPM formation. Leukotrienes 119-121 arachidonate 5-lipoxygenase activating protein Homo sapiens 31-35 35173459-2 2022 Proinflammatory leukotrienes (LTs), generated by 5-lipoxygenase (LOX) and the 5-LOX-activating protein (FLAP), initiate and maintain inflammation while specialized pro-resolving mediators (SPMs) formed by various LOXs as key enzymes promote inflammation resolution and the return to homeostasis. Leukotrienes 16-28 arachidonate 5-lipoxygenase activating protein Homo sapiens 104-108 30869888-1 2019 5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the production of proinflammatory and vasoactive leukotrienes. Leukotrienes 154-166 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 30929436-1 2019 5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. Leukotrienes 110-121 arachidonate 5-lipoxygenase activating protein Homo sapiens 42-46 28784429-0 2018 Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis. Leukotrienes 104-115 arachidonate 5-lipoxygenase activating protein Homo sapiens 71-75 30291962-8 2019 These data suggest that the KKK motif limits 5-LOX activity and that this attenuated activity must be compensated by the presence of FLAP as a partner protein for effective LT biosynthesis. Leukotrienes 173-175 arachidonate 5-lipoxygenase activating protein Homo sapiens 133-137 28784429-2 2018 Cellular leukotrienes are produced from arachidonic acid via the 5-lipoxygenase pathway in which the 5-lipoxygenase activating protein, also named as FLAP, plays a critical role by operating as a regulatory protein for efficient transfer of arachidonic acid to 5-lipoxygenase. Leukotrienes 9-21 arachidonate 5-lipoxygenase activating protein Homo sapiens 150-154 28784429-3 2018 By blocking leukotriene production, FLAP inhibitors may behave as broad-spectrum leukotriene modulators, which might be of therapeutic use for chronic inflammatory diseases requiring anti-leukotriene therapy. Leukotrienes 12-23 arachidonate 5-lipoxygenase activating protein Homo sapiens 36-40 28784429-3 2018 By blocking leukotriene production, FLAP inhibitors may behave as broad-spectrum leukotriene modulators, which might be of therapeutic use for chronic inflammatory diseases requiring anti-leukotriene therapy. Leukotrienes 81-92 arachidonate 5-lipoxygenase activating protein Homo sapiens 36-40 28784429-3 2018 By blocking leukotriene production, FLAP inhibitors may behave as broad-spectrum leukotriene modulators, which might be of therapeutic use for chronic inflammatory diseases requiring anti-leukotriene therapy. Leukotrienes 81-92 arachidonate 5-lipoxygenase activating protein Homo sapiens 36-40 28160477-1 2017 Objectives: The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. Leukotrienes 96-108 arachidonate 5-lipoxygenase activating protein Homo sapiens 16-62 28005436-2 2017 The biosynthesis of LTs mainly involves 5-lipoxygenase (5-LO) and its 5-lipoxygenase-activating protein (FLAP), LTA4 hydrolase and LTC4 synthase that all may represent potential targets for LT biosynthesis inhibitors. Leukotrienes 20-23 arachidonate 5-lipoxygenase activating protein Homo sapiens 105-109 29597170-0 2018 Identification of multi-target inhibitors of leukotriene and prostaglandin E2 biosynthesis by structural tuning of the FLAP inhibitor BRP-7. Leukotrienes 45-56 arachidonate 5-lipoxygenase activating protein Homo sapiens 119-123 28839250-2 2017 Whereas the 5-lipoxygenase-activating protein (FLAP) facilitates AA conversion by 5-lipoxygenase (5-LOX) to pro-inflammatory leukotrienes (LTs), the soluble epoxide hydrolase (sEH) degrades anti-inflammatory epoxyeicosatrienoic acids (EETs). Leukotrienes 125-137 arachidonate 5-lipoxygenase activating protein Homo sapiens 47-51 28839250-2 2017 Whereas the 5-lipoxygenase-activating protein (FLAP) facilitates AA conversion by 5-lipoxygenase (5-LOX) to pro-inflammatory leukotrienes (LTs), the soluble epoxide hydrolase (sEH) degrades anti-inflammatory epoxyeicosatrienoic acids (EETs). Leukotrienes 139-142 arachidonate 5-lipoxygenase activating protein Homo sapiens 47-51 28160477-1 2017 Objectives: The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. Leukotrienes 96-108 arachidonate 5-lipoxygenase activating protein Homo sapiens 64-71 28160477-1 2017 Objectives: The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. Leukotrienes 110-113 arachidonate 5-lipoxygenase activating protein Homo sapiens 16-62 28160477-1 2017 Objectives: The arachidonate 5-lipoxygenase activating protein (ALOX5AP) regulates synthesis of leukotrienes (LTs), which are important mediators of inflammation and connective tissue remodelling. Leukotrienes 110-113 arachidonate 5-lipoxygenase activating protein Homo sapiens 64-71 24905297-1 2014 BACKGROUND: Subcellular distribution of 5-lipoxygenase (5-LO) to the perinuclear region and interaction with the 5-LO-activating protein (FLAP) are assumed as key steps in leukotriene biosynthesis and are prone to FLAP antagonists. Leukotrienes 172-183 arachidonate 5-lipoxygenase activating protein Homo sapiens 138-142 29648709-1 2016 Leukotrienes (LTs) belong to pro-inflammatory mediators that are biosynthesized from arachidonic acid (AA), inter alia, by 5-lipoxygenase (5-LOX) enzyme in association with 5-LOX-activating protein (FLAP). Leukotrienes 0-12 arachidonate 5-lipoxygenase activating protein Homo sapiens 199-203 29648709-1 2016 Leukotrienes (LTs) belong to pro-inflammatory mediators that are biosynthesized from arachidonic acid (AA), inter alia, by 5-lipoxygenase (5-LOX) enzyme in association with 5-LOX-activating protein (FLAP). Leukotrienes 14-17 arachidonate 5-lipoxygenase activating protein Homo sapiens 199-203 27347071-1 2016 The aim of the present study was to investigate a possible association between the accumulation of rare coding variants in the genes for arachidonate 5-lipoxygenase (ALOX5) and ALOX5-activating protein (ALOX5AP), and corresponding production of leukotrienes (LTs) in patients with type 2 diabetes mellitus (T2DM) receiving acetylsalicylic therapy. Leukotrienes 245-257 arachidonate 5-lipoxygenase activating protein Homo sapiens 177-201 27347071-1 2016 The aim of the present study was to investigate a possible association between the accumulation of rare coding variants in the genes for arachidonate 5-lipoxygenase (ALOX5) and ALOX5-activating protein (ALOX5AP), and corresponding production of leukotrienes (LTs) in patients with type 2 diabetes mellitus (T2DM) receiving acetylsalicylic therapy. Leukotrienes 245-257 arachidonate 5-lipoxygenase activating protein Homo sapiens 203-210 27347071-1 2016 The aim of the present study was to investigate a possible association between the accumulation of rare coding variants in the genes for arachidonate 5-lipoxygenase (ALOX5) and ALOX5-activating protein (ALOX5AP), and corresponding production of leukotrienes (LTs) in patients with type 2 diabetes mellitus (T2DM) receiving acetylsalicylic therapy. Leukotrienes 259-262 arachidonate 5-lipoxygenase activating protein Homo sapiens 177-201 27347071-1 2016 The aim of the present study was to investigate a possible association between the accumulation of rare coding variants in the genes for arachidonate 5-lipoxygenase (ALOX5) and ALOX5-activating protein (ALOX5AP), and corresponding production of leukotrienes (LTs) in patients with type 2 diabetes mellitus (T2DM) receiving acetylsalicylic therapy. Leukotrienes 259-262 arachidonate 5-lipoxygenase activating protein Homo sapiens 203-210 26922224-0 2016 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP). Leukotrienes 54-65 arachidonate 5-lipoxygenase activating protein Homo sapiens 147-151 26922224-1 2016 In this article, we report novel leukotriene (LT) biosynthesis inhibitors that may target 5-lipoxygenase-activating protein (FLAP) based on the previously identified isoxazole derivative (8). Leukotrienes 33-44 arachidonate 5-lipoxygenase activating protein Homo sapiens 125-129 26944113-4 2016 ALOX5 gene encodes a 5"-lipoxygenase (5"-LO) activating protein (FLAP), a crucial component of the arachidonic acid/leukotriene inflammatory cascade. Leukotrienes 116-127 arachidonate 5-lipoxygenase activating protein Homo sapiens 65-69 25211287-3 2014 OBJECTIVE: To demonstrate expression of the leukotriene biosynthetic enzymes 5-lipoxygenase (5-LO), 5-lipoxygenase activating protein (FLAP), leukotriene A(4) hydrolase (LTA(4)H), and leukotriene C(4) synthase (LTC(4)S) in T and B tonsillar lymphocytes from pediatric patients with OSA. Leukotrienes 44-55 arachidonate 5-lipoxygenase activating protein Homo sapiens 135-139 28218273-2 2017 The biosynthesis of LTs is initiated by transfer of AA via the 5-lipoxygenase-activating protein (FLAP) to 5-lipoxygenase (5-LO). Leukotrienes 20-23 arachidonate 5-lipoxygenase activating protein Homo sapiens 98-102 27592027-0 2016 BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly. Leukotrienes 31-42 arachidonate 5-lipoxygenase activating protein Homo sapiens 145-149 27592027-1 2016 The pro-inflammatory leukotrienes (LTs) are formed from arachidonic acid (AA) in activated leukocytes, where 5-lipoxygenase (5-LO) translocates to the nuclear envelope to assemble a functional complex with the integral nuclear membrane protein 5-LO-activating protein (FLAP). Leukotrienes 21-33 arachidonate 5-lipoxygenase activating protein Homo sapiens 269-273 27592027-1 2016 The pro-inflammatory leukotrienes (LTs) are formed from arachidonic acid (AA) in activated leukocytes, where 5-lipoxygenase (5-LO) translocates to the nuclear envelope to assemble a functional complex with the integral nuclear membrane protein 5-LO-activating protein (FLAP). Leukotrienes 35-38 arachidonate 5-lipoxygenase activating protein Homo sapiens 269-273 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 104-115 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 104-115 arachidonate 5-lipoxygenase activating protein Homo sapiens 251-255 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 175-186 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 175-186 arachidonate 5-lipoxygenase activating protein Homo sapiens 251-255 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 175-186 arachidonate 5-lipoxygenase activating protein Homo sapiens 35-39 27129215-1 2016 5-Lipoxygenase activating protein (FLAP) plays a critical role in the metabolism of arachidonic acid to leukotriene A4, the precursor to the potent pro-inflammatory mediators leukotriene B4 and leukotriene C4 Studies with small molecule inhibitors of FLAP have led to the discovery of a drug binding pocket on the protein surface, and several pharmaceutical companies have developed compounds and performed clinical trials. Leukotrienes 175-186 arachidonate 5-lipoxygenase activating protein Homo sapiens 251-255 26173130-1 2015 5-Lipoxygenase (5-LO) catalyzes leukotriene (LT) biosynthesis by a mechanism that involves interactions with 5-lipoxygenase activating protein (FLAP) and coactosin-like protein (CLP). Leukotrienes 32-43 arachidonate 5-lipoxygenase activating protein Homo sapiens 144-148 24905297-1 2014 BACKGROUND: Subcellular distribution of 5-lipoxygenase (5-LO) to the perinuclear region and interaction with the 5-LO-activating protein (FLAP) are assumed as key steps in leukotriene biosynthesis and are prone to FLAP antagonists. Leukotrienes 172-183 arachidonate 5-lipoxygenase activating protein Homo sapiens 214-218 24681156-4 2014 Here, we investigate the efficacy of MK-886, an inhibitor of 5-lipoxygenase activating protein (FLAP), in blocking leukotriene synthesis, secondary brain damage, synaptic dysfunction, and cognitive impairments after TBI. Leukotrienes 115-126 arachidonate 5-lipoxygenase activating protein Homo sapiens 96-100 25034252-0 2014 Roles of coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP) in cellular leukotriene biosynthesis. Leukotrienes 95-106 arachidonate 5-lipoxygenase activating protein Homo sapiens 77-81 24641614-0 2014 The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). Leukotrienes 50-61 arachidonate 5-lipoxygenase activating protein Homo sapiens 144-148 23600432-1 2013 INTRODUCTION: 5-Lipoxygenase (5-LO) is a crucial enzyme of the arachidonic acid (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein. Leukotrienes 134-146 arachidonate 5-lipoxygenase activating protein Homo sapiens 170-174 23746795-3 2013 5-lipoxygenase activating (ALOX5AP) gene involved in the synthesis of leukotrienes, has been recognized as an important gene contributing towards susceptibility of stroke risk. Leukotrienes 70-82 arachidonate 5-lipoxygenase activating protein Homo sapiens 27-34 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 12-24 arachidonate 5-lipoxygenase activating protein Homo sapiens 215-219 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 12-24 arachidonate 5-lipoxygenase activating protein Homo sapiens 221-228 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 178-189 arachidonate 5-lipoxygenase activating protein Homo sapiens 215-219 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 178-189 arachidonate 5-lipoxygenase activating protein Homo sapiens 221-228 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 367-378 arachidonate 5-lipoxygenase activating protein Homo sapiens 215-219 23194405-1 2012 BACKGROUND: Leukotrienes are potent inflammatory mediators, which in a number of studies have been found to be associated with ischemic stroke pathology: gene variants affecting leukotriene synthesis, including the FLAP (ALOX5AP) gene, have in human studies shown correlation to stroke incidence, and animal studies have demonstrated protective properties of various leukotriene-disrupting drugs. Leukotrienes 367-378 arachidonate 5-lipoxygenase activating protein Homo sapiens 221-228